Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.36 |
| ▸ | KDM4A | O75164 | 2/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.36 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.36 |
| ▸ | TET3 | O43151 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Malonic Acid SCHEMBL28880678 | 0.81 | LDHA (0.60) | LDHASRRSMN1; SMN2SLC22A6TET2 | |
| SCHEMBL11465675 | 0.75 | — | — | |
| SCHEMBL1333038 | 0.74 | LMNA (0.50) | SMN1; SMN2SLC22A6TET2KDM4AKDM4C | |
| SCHEMBL2580779 | 0.73 | — | — | |
| SCHEMBL7077910 | 0.73 | LDHA (0.47) | LDHASRRSMN1; SMN2SLC22A6TET2 | |
| SCHEMBL9423742 | 0.71 | — | — | |
| SCHEMBL1847901 | 0.71 | LMNA (0.40) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL165376 | 0.71 | — | — | |
| SCHEMBL2181353 | 0.71 | — | — | |
| SCHEMBL6058674 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116003245-A | Preparation method of 2-hydroxy-3-oxopentane diacid | 苏州永健生物医药有限公司 | 2023-04-25 | — | — | CN | claimed |
| US-20200231527-A1 | SYNTHESIS OF ORGANIC ACIDS FROM ALPHA-KETO ACIDS | FURMAN UNIVERSITY | 2020-07-23 | — | — | US | claimed |
| CN-116847871-A | Skin care compositions and methods of use | 现代牧场股份有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116003245-A | Preparation method of 2-hydroxy-3-oxopentane diacid | 苏州永健生物医药有限公司 | 2023-04-25 | — | — | CN | disclosed |
| US-11505519-B2 | Synthesis of organic acids from α-keto acids | FURMAN UNIVERSITY (US) | 2022-11-22 | — | — | US | disclosed |
| EP-3911624-A1 | SYNTHESIS OF ORGANIC ACIDS FROM ALPHA-KETO ACIDS | Furman University (US) | 2021-11-24 | — | — | EP | disclosed |
| US-20200231527-A1 | SYNTHESIS OF ORGANIC ACIDS FROM ALPHA-KETO ACIDS | FURMAN UNIVERSITY | 2020-07-23 | — | — | US | disclosed |
| WO-2020150568-A1 | SYNTHESIS OF ORGANIC ACIDS FROM ALPHA-KETO ACIDS | FURMAN UNIVERSITY (US) | 2020-07-23 | — | — | WO | disclosed |
| EP-3153580-A2 | ALDOLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | BASF Enzymes LLC (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-2867669-B1 | Methods for identifying diabetes drugs | METANOMICS HEALTH GMBH (DE) | 2016-12-21 | — | — | EP | disclosed |
| EP-2385108-B1 | Aldolases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2016-11-23 | — | — | EP | disclosed |
| EP-2112227-A1 | Aldolases, nucleic acids encoding them and methods for making and using them | Cargill, Incorporated (US) | 2009-10-28 | — | — | EP | disclosed |
| EP-1999256-A4 | ALDOLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | VERENIUM CORP (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1999256-A2 | ALDOLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | Verenium Corporation (US) | 2008-12-10 | — | — | EP | disclosed |
| EP-1994161-A2 | ALDOLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | CARGILL, INCORPORATED (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20080020435-A1 | Aldolases, nucleic acids encoding them and methods for making and using them | CARGILL, INCORPORATED (US) | 2008-01-24 | — | — | US | disclosed |
| WO-2007103989-A9 | ALDOLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | VERENIUM CORP (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007103389-A9 | ALDOLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | CARGILL INC (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007103389-A2 | ALDOLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | CARGILL, INCORPORATED (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007103989-A2 | ALDOLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | VERENIUM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231527-A1 | SYNTHESIS OF ORGANIC ACIDS FROM ALPHA-KETO ACIDS | HOGA1, BCKDK, PCCA | LDHA 213/4885SRR 1601/4885SMN1; SMN2 4397/4885 |
| US-11505519-B2 | Synthesis of organic acids from α-keto acids | HOGA1, BCKDK, KHK | LDHA 210/4885SRR 1183/4885SMN1; SMN2 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.